Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]
Topic prioritisation
The topic was discussed at the Topic Selection Oversight Panel (TSOP) in July 2022.
Current NICE guidance already exists for natalizumab in relapsing-remitting MS (NICE TA127), yet this does not include a recommendation for highly active relapsing-remitting. Since the publication of TA127 in 2007, the subcutaneous formulation has received marketing authorisation, and it has been confirmed that natalizumab subcutaneous will continue to be commissioned across the NHS in the UK in-line with TA127.
The panel concluded that conducting a separate evaluation of natalizumab for highly active relapsing-remitting multiple sclerosis would not be appropriate at this time. Should there be significant new evidence in the ‘highly active’ group, a part review of TA127 would be considered.